A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-6624 Combined with FOLFIRI as Second Line Treatment for Metastatic KRAS Mutant Colorectal Adenocarcinoma that Has Progressed Following a First Line Oxaliplatin- and Fluoropyrimidine-Containing Regimen.

Summary:
GS-6624 is an experimental agent being developed to treat many different diseases, including myelofibrosis. This study aims to find out what effects, good and/or bad, GS-6624 has on patients with Colorectal Adenocarcinoma when it is given with FOLFIRI, which is approved by the FDA for this type of cancer.

Eligibility and Treatment Plan:
• 18 years of age and older
• Patients with cancer of the colon or rectum
• Patient must have received first-line combination therapy containing oxaliplatin and a fluoropyrimidine
• Stage IV disease

Please call for more information.